Compare Neurocrine Biosciences Inc (NBIX) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs UiPath Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while UiPath Inc trades at $13.59 (market cap $7.26B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.2× UiPath Inc's market cap. Which is the better fit depends on your goals.
| NBIX | PATH | |
|---|---|---|
Market Cap | $15.77B | $7.26B |
Sector | Health | Technology |
52-Week High | $185.50 | $19.29 |
52-Week Low | $123.10 | $9.38 |
Enterprise Value | $15.78B | $6.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
UiPath (PATH) trades at $14.01, down 7.77% amid mixed signals. The stock is near its consensus price target low of $14.00. Revenue growth is improving, with 2025 revenue at $1.43 billion and a projected net profit margin of 21.03% for 2026. Technical indicators show a bearish near-term trend with RSI at oversold levels, while recent news highlights volatility following Q2 earnings.
The outlook is cautious; PATH shows fundamental improvement but faces execution risks and competitive pressure. Analyst consensus is predominantly Hold (70.84%), with a $17.38 price target suggesting modest upside. Key risks include slowing growth guidance and macroeconomic headwinds impacting software demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
